Standardized SM screening and diagnostic testing implemented 1 July 2021
| . | References . |
|---|---|
| Screening tests | |
| 1. Presence of monomorphic MPCM? (yes or no) | 3,25 |
| 2. Presence of high-risk anaphylaxis (REMA Score ≥ 2)? (yes or no) | 27,54 |
| 3. Elevated BST based upon tryptase genotype? (yes or no) | 30,31 |
| Diagnostic testing quality checks | |
| 1. Was high-sensitivity KIT p.D816V quantitative PCR performed? (yes or no) | 37 |
| 2. Was CD117, tryptase, CD25, CD2 IHC performed? (yes or no) | 55 |
| 3. Was mast cell flow cytometry performed? (yes or no) | 56 |
| 4. Was the BM analyzed at a center of excellence? (yes or no) | 33,35,57 |
| . | References . |
|---|---|
| Screening tests | |
| 1. Presence of monomorphic MPCM? (yes or no) | 3,25 |
| 2. Presence of high-risk anaphylaxis (REMA Score ≥ 2)? (yes or no) | 27,54 |
| 3. Elevated BST based upon tryptase genotype? (yes or no) | 30,31 |
| Diagnostic testing quality checks | |
| 1. Was high-sensitivity KIT p.D816V quantitative PCR performed? (yes or no) | 37 |
| 2. Was CD117, tryptase, CD25, CD2 IHC performed? (yes or no) | 55 |
| 3. Was mast cell flow cytometry performed? (yes or no) | 56 |
| 4. Was the BM analyzed at a center of excellence? (yes or no) | 33,35,57 |